Assessment of Proarrhythmic Adverse Effects during Drug Development: Current Status and Challenges Ahead

Jules Hancox,
Professor of Cardiac Electrophysiology,School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom

Paul Volders,
Cardiologist and Principal Investigator,Department of Cardiology, CARIM, Maastricht University Medical Center, Maastricht, The Netherlands

Mechanisms of drug-induced arrhythmia: implications for cardiac safety evaluation of drugs in development
Professor Jules Hancox
Professor of Cardiac Electrophysiology, School of Physiology, Pharmacology and Neuroscience, University of Bristol, United Kingdom

Current approaches to the assessment of proarrhythmic potential of drugs and surrogate parameters of drug-induced arrhythmia
Dr Henk Van Der Linde
Principal Scientist, Janssen Pharmaceutical Company, Berlin

Oral communication speaker - to be confirmed in 2023.

Evaluation of the hidden cardiotoxic effects of COX2 inhibitors
Tamas Gergely
Department of Pharmacology and Pharmacotherapy, Semmelweis University Hungary, Budapest,
Hungary

Transgenic Rabbit Models for Proarrhythmia Prediction
Professor Dr Istvan Baczko
Department of Pharmacology and Pharmacotherapy, Albert Szent-Gyorgyi Medical School, University of Szeged, Hungary